Artificial Intelligence in Hemophilia Management: Revolutionizing Patient Care and Future Directions [0.03%]
人工智能在血友病管理中的应用：革新患者护理和未来发展方向
Sarina Levy-Mendelovich,Benjamin S Glicksberg,Shelly Soffer et al.
Sarina Levy-Mendelovich et al.
Recent advancements in artificial intelligence (AI) hold significant promise for transforming hemophilia care. This review explores AI's impact on critical aspects of hemophilia management, including bleeding risk prediction, biomarker iden...
Anna Torrent,Josep Maria Ribera
Anna Torrent
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has historically been associated with poor prognosis and limited therapeutic options. Over the past two decades, however, the treatment paradigm has markedly shifted. T...
Integrating AI into Hematology: New Frontiers and Practical Applications [0.03%]
人工智能在血液学中的应用：新前沿与实践展望
Shelly Soffer,Eyal Klang
Shelly Soffer
Editorial
Acta haematologica. 2025 Jun 13:1-5. DOI:10.1159/000546889 2025
Machine learning application for bleeding risk prediction in patients with atrial fibrillation treated with oral anticoagulation [0.03%]
口服抗凝治疗的心房颤动患者的出血风险预测的机器学习应用
Tsahi T Lerman,Shmuel Tiosano,Roy Beigel et al.
Tsahi T Lerman et al.
Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with a significantly increased risk of systemic thromboembolism and stroke. Anticoagulation therapy, particularly with Direct Oral Anticoagulants, has become the standard...
Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to Therapy [0.03%]
环形染色体在髓系肿瘤患者中与较差的治疗反应有关
Daniel I Nathan,Ronald Hoffman,Daiva Ahire et al.
Daniel I Nathan et al.
Introduction: Ring chromosomes (RC) are acquired circular structural abnormalities associated with gain or loss of genetic material, which are thought to be associated with inferior outcomes of patients with myeloid neopl...
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia [0.03%]
费城染色体阴性的新诊断急性淋巴细胞白血病老年患者的治疗
Lourdes M Mendez,Daniel J DeAngelo,Marlise R Luskin
Lourdes M Mendez
Approximately half of newly diagnosed cases of acute lymphoblastic leukemia (ALL) occur in adults, but adults experience significantly higher rates of treatment failure and treatment-related mortality due to frequent presence of adverse dis...
Ultrasonography-guided core-needle biopsy for newly diagnosed large B-cell lymphomas: analysis on diagnostic efficacy and safety in an Italian retrospective study [0.03%]
意大利一项回顾性研究：新诊断的大B细胞淋巴瘤超声引导空芯针活检的诊断价值和安全性分析
Marco Picardi,Claudia Giordano,Annamaria Vincenzi et al.
Marco Picardi et al.
Introduction: Excisional biopsy (EB) is the gold standard for large B-cell lymphomas (LBCLs) diagnosis. Based on recent advances in interventional radiology enabling accurate sampling with core needle biopsy (CNB), we eva...
AI Applications in Transfusion Medicine: Opportunities, Challenges, and Future Directions [0.03%]
人工智能在输血医学中的应用：机遇、挑战和未来方向
Merav Barzilai,Omri Cohen
Merav Barzilai
Artificial intelligence (AI) is reshaping healthcare, with its applications in transfusion medicine showing great promise to address longstanding challenges. This review explores the integration of AI-driven tools, including Machine Learnin...
Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia [0.03%]
细胞治疗之外：抗体驱动免疫疗法在儿童急性淋巴细胞白血病中角色的扩展
David McCall,Samanta Catueno,Ramya Ramakrishnan et al.
David McCall et al.
Background: The integration of novel antibody-mediated targeted therapies into both relapsed/refractory (R/R) and frontline pediatric acute lymphoblastic leukemia (ALL) treatment protocols has led to critical advancements...
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trial [0.03%]
严格的血管监测和降低剂量的 Ponatinib作为二线治疗方案对一线二代酪氨酸激酶抑制剂(TKI)治疗失败或不耐受的慢性期慢性粒细胞白血病(CML-CP)患者的血管事件有利：前瞻性PONS试验结果
Philipp le Coutre,Andreas Burchert,Susanne Saußele et al.
Philipp le Coutre et al.
Introduction: In chronic myeloid leukemia patients second-line treatment require careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowered...